{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:28:49Z","timestamp":1775834929300,"version":"3.50.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, but preclinical testing of hypotheses such as combination therapies has been complicated, in part due to species incompatibility issues. For example, one of few known permissive animal models for oncolytic adenoviruses is the Syrian hamster, for which an ICI, mainly an anti-PD-L1 monoclonal antibody (mAb) was not previously available. In this study, we developed an anti-Syrian hamster PD-L1 mAb to enable the evaluation of safety and efficacy, when combining anti-PD-L1 with an oncolytic adenovirus encoding tumour necrosis factor alpha (TNF\u03b1) and interleukin-2 (IL-2) (Ad5\/3-E2F-D24-hTNF\u03b1-IRES-hIL-2 or TILT-123).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Recombinant Syrian hamster PD-L1 was expressed and mice immunized for mAb formation using hybridoma technology. Clonal selection through binding and functional studies in vitro, in silico and in vivo identified anti-PD-L1 clone 11B12-1 as the primary mAb candidate for immunotherapy modelling. The oncolytic virus (OV) and ICI combination approach was then evaluated using 11B12-1 and TILT-123 in a Syrian hamster model of pancreatic ductal adenocarcinoma (PDAC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Supernatants from hybridoma parent subclone 11B12B4 provided the highest positive PD-L1 signal, on Syrian hamster PBMCs and three cancer cell lines (HT100, HapT1 and HCPC1). In vitro co-cultures revealed superior immune modulated profiles of cell line matched HT100 tumour infiltrating lymphocytes when using subclones of 7G2, 11B12 and 12F1. Epitope binning and epitope prediction using AlphaFold2 and ColabFold revealed two distinct functional epitopes for clone 11B12-1 and 12F1-1. Treatment of Syrian hamsters bearing HapT1 tumours, with 11B12-1 induced significantly better (p&amp;lt;0.05) tumour growth control than isotype control by day 12. 12F1-1 did not induce significant tumour growth control. The combination of 11B12-1 with oncolytic adenovirus TILT-123 improved tumour growth control further, when compared to monotherapy (p&amp;lt;0.05) by day 26.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Novel Syrian hamster anti-PD-L1 clone 11B12-1 induces tumour growth control in a hamster model of PDAC. Combining 11B12-1 with oncolytic adenovirus TILT-123 improves tumour growth control further and demonstrates good safety and toxicity profiles.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1060540","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:41:07Z","timestamp":1675424467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting"],"prefix":"10.3389","volume":"14","author":[{"given":"James H. A.","family":"Clubb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana V.","family":"Kudling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mykhailo","family":"Girych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyna","family":"Haybout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santeri","family":"Pakola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Cervera-Carrascon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabrita","family":"Hemmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Gr\u00f6nberg-V\u00e4h\u00e4-Koskela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Manuel","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafne C. A.","family":"Quixabeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saru","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Heini\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Jirovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreyas","family":"Kaptan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suvi","family":"Sorsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Erikat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjukka","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katri","family":"Aro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapani","family":"Viitala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilpo","family":"Vattulainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/5584_2016_135","article-title":"Syrian Hamsters as a small animal model for emerging infectious diseases: advances in immunologic methods","volume-title":"Emerging and re-emerging viral infections","author":"Warner","year":"2016"},{"key":"B2","first-page":"195","article-title":"Diet-induced metabolic hamster model of nonalcoholic fatty liver disease","volume":"4","author":"Bhathena","year":"2011","journal-title":"Diab Metab syndrome obesity: Targets Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-7075-7-89","article-title":"Use of hamster as a model to study diet-induced atherosclerosis","volume":"7","author":"Dillard","year":"2010","journal-title":"Nutr Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvs368","article-title":"Lipidomic and metabolomic analyses reveal potential plasma biomarkers of early atheromatous plaque formation in hamsters","volume":"97","author":"Jove","year":"2013","journal-title":"Cardiovasc Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2012.09.064","article-title":"Aggressive experience increases dendritic spine density within the nucleus accumbens core in female Syrian hamsters","volume":"227","author":"Staffend","year":"2012","journal-title":"Neuroscience"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3390\/cells11152395","article-title":"Golden Syrian hamster models for cancer research","volume":"11","author":"Wang","year":"2022","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa325","article-title":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility","volume":"71","author":"Chan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian Hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2\u2013 infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.xcrm.2020.100121","article-title":"Oral SARS-CoV-2 inoculation establishes subclinical respiratory infection with virus shedding in golden Syrian hamsters","volume":"1","author":"Lee","year":"2020","journal-title":"Cell Rep Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/v12070779","article-title":"Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters","volume":"12","author":"Osterrieder","year":"2020","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1858177","article-title":"Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection","volume":"9","author":"Rosenke","year":"2020","journal-title":"Emerging Microbes infections"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73522","article-title":"Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection","volume":"11","author":"Rizvi","year":"2022","journal-title":"Elife"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian Hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab128","article-title":"An immune-competent, replication-permissive Syrian hamster glioma model for evaluating delta-24-RGD oncolytic adenovirus","volume":"23","author":"Phillips","year":"2021","journal-title":"Neuro-oncology"},{"key":"B19","article-title":"Syngeneic Syrian hamster tumours feature tumour-infiltrating lymphocytes allowing adoptive cell therapy enhanced","volume":"23","author":"Siurala","year":"2016","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic adenoviruses armed with tumour necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol Therapy-Oncolytics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30839","article-title":"Adenoviral production of interleukin-2 at the tumour site removes the need for systemic postconditioning in adoptive cell therapy","volume":"141","author":"Santos","year":"2017","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.005","article-title":"Abscopal effect in non-injected tumours achieved with cytokine-armed oncolytic adenovirus","volume":"11","author":"Havunen","year":"2018","journal-title":"Mol Therapy-Oncolytics"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3389\/fimmu.2021.674400","article-title":"Oncolytic adenovirus coding for a variant interleukin 2 (vIL-2) cytokine re-programs the tumour microenvironment and confers enhanced tumour control","volume":"12","author":"Quixabeira","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"2096572","DOI":"10.1080\/2162402X.2022.2096572","article-title":"Local delivery of interleukin 7 with an oncolytic adenovirus activates tumour-infiltrating lymphocytes and causes tumour regression","volume":"11","author":"Kudling","year":"2022","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8627","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic viruses and immune checkpoint inhibitors: preclinical developments to clinical trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/B978-0-12-802151-4.00007-4","article-title":"Commonly used animal models","author":"Hickman","year":"2017","journal-title":"Principles Anim Res graduate undergraduate students"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1099\/0022-1317-40-1-45","article-title":"Infection of mouse liver by human adenovirus type 5","volume":"40","author":"Duncan","year":"1978","journal-title":"J Gen Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.5.1651","article-title":"A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia","volume":"88","author":"Ginsberg","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.784947","article-title":"Humanized mice as a valuable pre-clinical model for cancer immunotherapy research","volume":"11","author":"Cogels","year":"2021","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1490856","article-title":"CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy","volume":"7","author":"Zafar","year":"2018","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNF\u03b1 and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"OncoImmunology"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1761229","article-title":"Tumour microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition","volume":"9","author":"Cervera-Carrascon","year":"2020","journal-title":"OncoImmunology"},{"key":"B33","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.3389\/fimmu.2021.706517","article-title":"Adenovirus armed with TNF\u03b1 and IL2 added to aPD-1 regimen mediates antitumour efficacy in tumours refractory to aPD-1","volume":"12","author":"Cervera-Carrascon","year":"2021","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.794251","article-title":"Adenovirus encoding tumour necrosis factor alpha and interleukin 2 induces a tertiary lymphoid structure signature in immune checkpoint inhibitor refractory head and neck cancer","volume":"13","author":"Clubb","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2028960","article-title":"Local therapy with an engineered oncolytic adenovirus enables antitumour response in non-injected melanoma tumours in mice treated with aPD-1","volume":"11","author":"Quixabeira","year":"2022","journal-title":"OncoImmunology"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002894","article-title":"Novel non-terminal tumour sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models","volume":"9","author":"Sitnikova","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat Methods"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.04.463034","article-title":"Protein complex prediction with AlphaFold-multimer","author":"Evans","year":"2021","journal-title":"BioRxiv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2016","journal-title":"J Chem Theory Comput"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J Chem Theory Comput"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/jp8001614","article-title":"Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations","volume":"112","author":"Joung","year":"2008","journal-title":"J Phys Chem B"},{"key":"B44","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J Chem Phys"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1063\/1.464397","article-title":"Particle mesh ewald: An n \u00b7log( n ) method for ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J Chem Phys"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/prot.21123","article-title":"Comparison of multiple amber force fields and development of improved protein backbone parameters","volume":"65","author":"Hornak","year":"2006","journal-title":"Proteins: Structure Function Bioinf"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J Comput Chem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1021\/ct5010406","article-title":"Long-time-step molecular dynamics through hydrogen mass repartitioning","volume":"11","author":"Hopkins","year":"2015","journal-title":"J Chem Theory Comput"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J Mol Graphics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"130015","DOI":"10.1016\/j.colsurfa.2022.130015","article-title":"Protein A\/G-based surface plasmon resonance biosensor for regenerable antibody-mediated capture and analysis of nanoparticles","volume":"654","author":"Parkkila","year":"2022","journal-title":"Colloids Surfaces A: Physicochemical Eng Aspects"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-016-1036-8","article-title":"Immunoglobulin G (IgG)-based imaging probe accumulates in M1 macrophage-infiltrated atherosclerotic plaques independent of IgG target molecule expression","volume":"19","author":"Shimizu","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-010-0022-1","article-title":"A dimeric structure of PD-L1: functional units or evolutionary relics","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1210-1248","article-title":"Towards a knowledge-based human protein atlas","volume":"28","author":"Uhlen","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/cancers11091400","article-title":"Blockade of PD-L1 enhances cancer immunotherapy by regulating dendritic cell maturation and macrophage polarization","volume":"11","author":"Sun","year":"2019","journal-title":"Cancers"},{"key":"B58","doi-asserted-by":"publisher","first-page":"105429","DOI":"10.1016\/j.phrs.2021.105429","article-title":"TRIM47 accelerates aerobic glycolysis and tumour progression through regulating ubiquitination of FBP1 in pancreatic cancer","volume":"166","author":"Li","year":"2021","journal-title":"Pharmacol Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0814","article-title":"Host IDO2 gene status influences tumour progression and radiotherapy response in KRAS-driven sporadic pancreatic CancersIDO2 polymorphisms affect pancreas cancer and radioresponse","volume":"25","author":"Nevler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079064","article-title":"Downregulation of IFNG in CD4+ T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression","volume":"8","author":"Wang","year":"2013","journal-title":"PLos One"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-18611-z","article-title":"Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors","volume":"12","author":"Matoba","year":"2022","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(83)90119-0","article-title":"Detection and characterization of natural killer cells in Syrian golden hamsters","volume":"19","author":"Teale","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw174","article-title":"Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer","volume":"27","author":"Chatterjee","year":"2016","journal-title":"Ann Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms6997","article-title":"PD-L1hi b cells are critical regulators of humoral immunity","volume":"6","author":"Khan","year":"2015","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"101960","DOI":"10.1016\/j.isci.2020.101960","article-title":"Human and mouse PD-L1: Similar molecular structure, but different druggability profiles","volume":"24","author":"Magiera-Mularz","year":"2021","journal-title":"Iscience"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1060540\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:41:22Z","timestamp":1675424482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1060540\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2023.1060540"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1060540","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"article-number":"1060540"}}